Regulatory Hurdles and Evidence Gaps

Chief Executive Officer Matthew Klein announced the withdrawal on Thursday, following feedback from federal regulators. According to Klein, the FDA's review indicated that the data in the New Drug Application was unlikely to meet the agency's "substantial evidence of effectiveness" threshold. Consequently, the company chose to pull the submission rather than proceed toward a likely rejection.

The therapy was designed to treat nonsense mutation Duchenne muscular dystrophy, a rare and fatal genetic disorder that leads to progressive muscle degeneration. This regulatory setback represents a significant blow to PTC's efforts to commercialize the drug in the United States, where evidence requirements for rare disease treatments remain a point of intense scrutiny.

Market Reaction

Investors reacted swiftly to the news, sending PTC Therapeutics shares down 5.2% to $67.05 in post-market trading. The stock had finished the regular session at $70.70. Despite the drop, the company’s valuation has remained robust over the longer term, with the stock climbing 44% over the past year.